Merck suffers bad week as 3 Keytruda combination trials fail

Merck & Co.’s reputation for picking winners in cancer treatment took a hit this week as the New Jersey-based drugmaker reported three separate failures of trials that combined its immunotherapy Keytruda with other agents.